Analyst ratings for Augmedix (NASDAQ:AUGX) show a mix of opinions, with recent actions including both upgrades and downgrades. The average 12-month price target is $5.00, with a high of $5.50 and a low of $4.50, marking a 14.24% decline from the previous average. Augmedix's financial performance shows strong revenue growth and net margin, but challenges in asset utilization and higher debt levels. Analysts' ratings and price targets reflect their views on the company's future performance relative to market conditions.